Interventions du FILO à l'ASH 2024 dans le domaine de la LAM
VAMOR
Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study
Communication orale présentée par Jules HIGUÉ
Number: 58
Presenter: Jules Higué
Session: 617. Acute Myeloid Leukemias: Commercially Available Therapies: How Do We Start? Upfront Regimens with Commercially Available Therapies
Time and Location: 7 Déc 2024 10:15
BIG-1
Poster présenté par Régis PEFFAULT DE LATOUR
Number: 3483
Presenter: Régis Peffault De Latour
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster II
Time and Location: 8 Déc 2024 18:00-20:00
BIG-1
Poster présenté par Edouard FORCADE
Number: 4909
Presenter: Edouard FORCADE
Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster III
Time and Location: 9 Déc 2024 18:00-20:00
BIG-1
Communication orale présentée par Adriana PLESA
Result Type: Oral
Number: 226
Presenter: Adriana Plesa
Program: Oral and Poster Abstracts
Session: 619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Measurable Residual Disease in AML in 2024 and Beyond
Time and Location: 7 Déc 2024 14:45